Russell Rocha
Family · Jupiter, FLNPI 1235837030
Payments from drug & device makers
Across 88 payments — averaging $19.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$310
- Pfizer$261
- Novo Nordisk$179
- AstraZeneca$170
- Amgen$125
- Novartis$96
- plus $549 from 17 others
What the payments were for
- Food & beverage$1,690100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 18 | $310 |
| Pfizer | 16 | $261 |
| Novo Nordisk | 10 | $179 |
| AstraZeneca | 8 | $170 |
| Amgen | 4 | $125 |
| Novartis | 5 | $96 |
| GSK | 6 | $92 |
| Boston Scientific | 3 | $77 |
| Daiichi Sankyo Inc. | 2 | $42 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $38 |
| Lilly USA, LLC | 2 | $36 |
| Actelion Pharmaceuticals US, Inc. | 1 | $31 |
| Sanofi-aventis U.S. LLC | 1 | $30 |
| Seqirus USA Inc | 1 | $29 |
| Corium, LLC | 1 | $26 |
| Tris Pharma Inc | 1 | $25 |
| Exact Sciences | 1 | $21 |
| Merck | 1 | $20 |
| Noven Therapeutics, LLC | 1 | $19 |
| Boehringer Ingelheim | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Halozyme Inc | 1 | $14 |
| Cleerly, Inc. | 1 | $14 |
How this compares
$1,690 in reported general payments places this provider in the 75th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 13 | $11,417 |
| MounjaroTirzepatide | 11 | $11,300 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 29 | $568 |
| Rosuvastatin Calcium | 48 | $498 |
| Metoprolol Succinate | 32 | $395 |
| Methylprednisolone | 57 | $350 |
| Lisinopril | 41 | $301 |
| Atorvastatin Calcium | 35 | $282 |
| Levothyroxine Sodium | 40 | $281 |
| Ezetimibe | 11 | $263 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 15 | $261 |
| Amlodipine Besylate | 49 | $255 |
| Prednisone | 52 | $245 |
| Gabapentin | 16 | $245 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 29 | $231 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $18 | $11,41713 claims |
| Lilly USA, LLCMounjaro | $36 | $11,30011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 14,618 family providers in Florida.
Other family in Jupiter
- Jennifer KuretskiJupiter$180K
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.